Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TR004 regulatory T-cell immunotherapy in Crohn's disease
ISRCTN97547683Phase 2Completed
- Sponsor
- King's College London
- Start
- Aug 2022
- Modality
- Cell Therapies
01
Overview
Phase 2, randomised, double-blind trial of TR004 in Crohn's disease (2 arms), sponsored by King's College London. Primary endpoint: Number of dose-limiting toxicities. Started Aug 2022; status: completed.
02
Drugs
TR004
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ISRCTN97547683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN97547683.